BioAffinity Technologies Total Long Term Liabilities 2022-2025 | BIAF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioAffinity Technologies total long term liabilities from 2022 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

BioAffinity Technologies Total Long Term Liabilities 2022-2025 | BIAF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioAffinity Technologies total long term liabilities from 2022 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$225.3B
Amgen (AMGN)	$164.8B
Gilead Sciences (GILD)	$144.5B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.4B
GSK (GSK)	$77.7B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$42.9B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.7B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.7B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$17.3B
Genmab (GMAB)	$15B
Genmab (GNMSF)	$15B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.4B
QIAGEN (QGEN)	$11.5B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8B
Roivant Sciences (ROIV)	$7.9B